PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation

Histopathology

Volumn 69, Issue 2, 2016, Pages 177-186

  Cree, Ian A ^a   Booton, Richard ^b   Cane, Paul ^c   Gosney, John ^d   Ibrahim, Merdol ^e   Kerr, Keith ^f   Lal, Rohit ^c   Lewanski, Conrad ^g   Navani, Neal ^h   Nicholson, Andrew G ⁱ   Nicolson, Marianne ^j   Summers, Yvonne ^k  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UK National External Quality Assessment Service Immunocytochemistry and In situ Hybridization   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

ⁱ ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^j ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^k CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

immunohistochemistry; immunotherapy; non small cell lung cancer; programmed death ligand 1; programmed death receptor 1; quality assurance; specimen handling; treatment stratification

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TISSUE SECTION; UNITED KINGDOM;

EID: 84978274900     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12996     Document Type: Review

References (28)

1. Globocan 2012. Lung cancer: estimated incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 3 May 2016).
2. Royal College of Physicians. National Lung Cancer Audit annual report 2014. Available at: https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2014 (accessed 3 May 2016).
3. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small cell lung cancer (NSCLC). Clin. Lung Cancer 2012; 13; 252–266.
4. Brandao GD, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma—now and in the future. Curr. Oncol. 2012; 19(Suppl. 1); S24–S32.
5. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011; 3; 75–83.
6. Brahmer JR. Harnessing the immune system for the treatment of non-small cell lung cancer. J. Clin. Oncol. 2013; 31; 1021–1028.
7. Chen YB, Mu CY, Huang JA. Clinical significance of programmed cell death-1 ligand expression in patients with non-small cell lung cancer: a 5-year follow-up study. Tumori 2012; 98; 751–755.
8. Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin. Oncol. 2015; 42(Suppl. 2); S11–S18.
9. Kerr KM, Ming-Sound T, Nicholson AG et al. Programmed death ligand 1 immunohistochemistry in lung cancer: in what state is this art? J. Thorac. Oncol. 2015; 10; 985–989.
10. Yao X, Gomes MM, Tsao MS et al. Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. Curr. Oncol. 2012; 19; e16–e27.
11. Overman MJ, Modak J, Kopetz S et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J. Clin. Oncol. 2013; 31; 17–22.
12. Tam AL, Kim ES, Lee JJ et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J. Thorac. Oncol. 2013; 8; 436–442.
13. José RJ, Shaw P, Taylor M et al. Impact of EBUS-TBNA on modalities for tissue acquisition in patients with lung cancer. QJM 2014; 107; 201–206.
14. Navani N, Brown JM, Nankivell M et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am. J. Respir. Crit. Care Med. 2012; 185; 1316–1322.
15. Evison M, Crosbie PA, Martin J et al. EBUS-TBNA in elderly patients with lung cancer: safety and performance outcomes. J. Thorac. Oncol. 2014; 9; 370–376.
16. Navani N, Nankivell M, Lawrence DR et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir. Med. 2015; 3; 282–289.
17. Park S, Holmes-Tisch AJ, Cho EY et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 2009; 4; 809–815.
18. Yoon HJ, Lee HY, Lee KS et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 2012; 265; 939–948.
19. Chouaid C, Dujon C, Do P et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer 2014; 86; 170–173.
20. Cree IA, Deans Z, Ligtenberg MJ et al. Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 2014; 67; 923–931.
21. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC eds. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
22. Ibrahim M, Parry S, Wilkinson D et al. Non-small cell lung carcinoma (NSCLC) ALK IHC EQA. Run 109 assessment results. UK NEQAS ICC & ISH Immunocytochem. J. 2015; 109; 2–11.
23. Rabenau HF, Kessler HH, Kortenbusch M et al. Verification and validation of diagnostic laboratory tests in clinical virology. J. Clin. Virol. 2007; 40; 93–98.
24. Rakha EA, Pinder SE, Bartlett JM et al. Updated UK Recommendations for HER2 assessment in breast cancer. J. Clin. Pathol. 2015; 68; 93–99.
25. Helliwell T, Giles T, Fensome-Rimmer S. ISO 15189:2012—an approach to the assessment of uncertainty of measurement for cellular pathology laboratories May 2015. Available at: http://www.rcpath.org/publications-media/publications (accessed 3 May 2016).
26. Maxwell P, McQuaid S, Salto Tellez M. The management of uncertainty: increasing stringency for validation and verification of immunohistochemistry in tissue diagnostics. UK NEQAS ICC & ISH Immunocytochem. J. 2014; 106; 5–6.
27. Ratcliffe M, Sharpe A, Midha A, Barker C, Scorer P, Walker J. A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016; LB-094.
28. Averbuch S, Emancipator K, McCaffery I et al. A blueprint proposal for companion diagnostic comparability. Available at: http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Documents/FDA-AACR-ASCO-Complexities-in-Personalized-Medicine-Blueprint-Proposal.pdf (accessed 3 May 2016).